InSite rationalizes

InSite Vision Inc. said it is tightening its strategic focus to concentrate on its clinical candidates for glaucoma and pterygium, a non-cancerous growth on the eye, which offer the greatest near term potential. The products include BetaSite, a formulation of the beta blocker levobunolol in INSV's DuraSite bioadhesive polymer, and PilaSite, a similar formulation of pilocarpine. Both are being developed